45PCost-effectiveness analysis of VEGF-A testing to predict response to bevacizumab (BEV) as a component of neo-adjuvant therapy of early HER-2 negative breast cancer
| Autor: | Blank, P.R., Loibl, S., Linderholm, B.K., Caramuta, S., Nekljudova, V., Szucs, T.D., Van Stiphout, J., Ademi, Z., von Minckwitz, G., Schwenkglenks, M. |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|